TANG KEVIN purchased $5K of BOLD (indirect holdings)

TANG KEVIN purchased 1,949 indirectly-held shares of Boundless Bio, Inc. (BOLD) at $2.40 across 2 trades over 2026-11-06 to 2026-11-10. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).

Original reporting
SEC EDGAR · TANG KEVIN, TANG CAPITAL MANAGEMENT LLC
Published Nov 10, 2026, 10:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BOLD
Neutral
high confidence
Mentioned
$BOLD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDNeutralLow
01

Why it matters

The purchase is a routine insider transaction with minimal market impact.

02

Market read

Low relevance; the filing provides a minor data point for insiders but no actionable trading signal.

03

What to watch

Potential future insider purchases could be more material; monitor future filings.

Relevance 3/10Novelty 3/10Timing: today

Background

Boundless Bio (BOLD) filed a Form 4 reporting an insider purchase of 1,949 shares at $2.40 each.

Company-level read

Ticker impact

$BOLDNeutralHigh confidence
Context

Form 4 shows insider Tang Kevin purchased 1,949 shares (~$4.7K) increasing his stake in Boundless Bio.

Expected impact

likely minimal upward pressure as market prices in the small buy.

Evidence & confidence

The transaction size is tiny relative to market cap; impact on price is expected to be marginal.

Market effects

None; insider activity does not affect sector trends.

None; the trade is too small to influence regional markets.

None; no broader market effect.

Counterpoint

Even small insider buys can signal confidence, but the amount is too trivial to act on.

Key entities

  • Boundless Bio, Inc.

    Biotech firm listed on NASDAQ under ticker BOLD.

  • Tang Kevin

    10% owner who increased his stake via the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BOLDMed

Boundless Bio 3Q 2026: EPS ($0.23) — 10-Q Summary

Boundless Bio reported a 61.4% narrower net loss of $5.36M in Q3 2026, with EPS at ($0.23). The reduction was driven by lower clinical-trial spending, reduced facilities, and personnel costs. The company also announced a 75% workforce reduction and expects a merger with Serapha Bio to close in Q4 2026, with a pre-closing dividend of $44M-$48M.